Neumora Therapeutics, Inc.
NMRA
$1.20
-$0.05-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.61% | 13.82% | 2.81% | 19.54% | 8.06% |
| Total Depreciation and Amortization | -90.39% | -90.63% | -67.04% | -44.38% | -25.57% |
| Total Amortization of Deferred Charges | 567.00% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.41% | -29.87% | -22.29% | -67.58% | -62.43% |
| Change in Net Operating Assets | -85.79% | -103.66% | -101.93% | -145.97% | 201.02% |
| Cash from Operations | 7.74% | 3.03% | -12.85% | -13.47% | 1.34% |
| Capital Expenditure | -- | -- | 100.00% | 99.70% | 100.00% |
| Sale of Property, Plant, and Equipment | 144.05% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.27% | 0.44% | 341.18% | -43.12% | 254.60% |
| Cash from Investing | -29.16% | 0.67% | 338.84% | -35.41% | 245.47% |
| Total Debt Issued | 110.69% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 135.85% | 55.90% | -7.75% | 133.65% | -92.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 121.53% | 100.00% |
| Cash from Financing | 121.58% | 345.21% | 256.84% | 510.81% | -84.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.91% | 133.89% | 116.89% | -8.26% | 48.88% |